Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions

Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals, is unveiling the Signals Clinical™ solution, a software-as-a-service (SaaS), end-to-end clinical data science platform designed to centralize all clinical trial data, providing fast, actionable insights for quicker clinical decisions and accelerated market delivery of therapeutics.

Acoramidis shows potential to be effective, safe treatment for transthyretin amyloid cardiomyopathy

Acoramidis improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with placebo, according to late-breaking research presented in a Hot Line session today at

August 28, 2023

New algorithm identifies cells responsible for aggressive tumor growth

Cancer Research UK-funded scientists have unveiled the first computational algorithm capable of identifying which cell populations within a tumor drive aggressive growth.

December 3, 2024

Added calcium and phosphate in fluoride varnishes no silver bullet for fighting kids’ tooth decay, study finds

The study explores the effectiveness of sodium fluoride varnishes with added calcium and phosphate versus conventional varnishes in reducing harmful bacteria in preschool children’s mouths.

November 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.